Manli Huang1, Liang Yu2, Fen Pan1, Shaojia Lu1, Shaohua Hu1, Jianbo Hu1, Jinkai Chen1, Pingbo Jin3, Hongli Qi1, Yi Xu4. 1. Department of Mental Health, First Affiliated Hospital, College of Medicine, Zhejiang University, The Key Laboratory of Mental Disorder Management of Zhejiang Province, No. 79, Qingchun Road, Hangzhou 310003, China. 2. Department of Anesthesiology and Pain, Hang Zhou First People's Hospital, No. 261, Huansha Road, Hangzhou 310006, China. 3. College of Medcine, Zhejiang University, No. 268, Kaixuan Road, Hangzhou 310000, China. 4. Department of Mental Health, First Affiliated Hospital, College of Medicine, Zhejiang University, The Key Laboratory of Mental Disorder Management of Zhejiang Province, No. 79, Qingchun Road, Hangzhou 310003, China. Electronic address: xuyizju@zju.edu.cn.
Abstract
BACKGROUND: This study was conducted to evaluate the efficacy and metabolic effects of paliperidone palmitate (PP) injections against oral olanzapine in first-episode schizophrenia (FES) patients. METHODS:Eligible patients were randomized to receive PP or olanzapine. Efficacy assessments and weight-related parameters were assessed at baseline, weeks 1, 5, 9, and endpoint or at early withdrawal. Lipid, glucose, insulin and prolactin were evaluated at baseline and endpoint or at early withdrawal. RESULTS: The Positive And Negative Syndrome Scale (PANSS) scores declined significantly after treatment in both groups. Significant increases in weight-related parameters from baseline to endpoint were shown in both groups. Although there was no significant difference in PANSS scores and weight-related parameters between the two groups through the whole 13-week study. The increased level of triglyceride and HOMA-IR at endpoint from baseline in the olanzapine group was higher than the PP group. There was a stronger elevation of prolactin level in the PP group. CONCLUSIONS: In summary, PP and olanzapine showed similar improvement in the treatment of FES patients. This study also reinforced the necessity for regular monitoring of metabolic parameters in schizophrenia patients prescribed atypical antipsychotics. Clinical trial registration numbers: ChiCTR-IOR-14005304. Date of registration: 2014-10-11.
RCT Entities:
BACKGROUND: This study was conducted to evaluate the efficacy and metabolic effects of paliperidone palmitate (PP) injections against oral olanzapine in first-episode schizophrenia (FES) patients. METHODS: Eligible patients were randomized to receive PP or olanzapine. Efficacy assessments and weight-related parameters were assessed at baseline, weeks 1, 5, 9, and endpoint or at early withdrawal. Lipid, glucose, insulin and prolactin were evaluated at baseline and endpoint or at early withdrawal. RESULTS: The Positive And Negative Syndrome Scale (PANSS) scores declined significantly after treatment in both groups. Significant increases in weight-related parameters from baseline to endpoint were shown in both groups. Although there was no significant difference in PANSS scores and weight-related parameters between the two groups through the whole 13-week study. The increased level of triglyceride and HOMA-IR at endpoint from baseline in the olanzapine group was higher than the PP group. There was a stronger elevation of prolactin level in the PP group. CONCLUSIONS: In summary, PP and olanzapine showed similar improvement in the treatment of FES patients. This study also reinforced the necessity for regular monitoring of metabolic parameters in schizophreniapatients prescribed atypical antipsychotics. Clinical trial registration numbers: ChiCTR-IOR-14005304. Date of registration: 2014-10-11.
Authors: Luisa Peters; Amanda Krogmann; Laura von Hardenberg; Katja Bödeker; Viktor B Nöhles; Christoph U Correll Journal: Curr Psychiatry Rep Date: 2019-11-19 Impact factor: 5.285
Authors: Marian S McDonagh; Tracy Dana; Shelley Selph; Emily B Devine; Amy Cantor; Christina Bougatsos; Ian Blazina; Sara Grusing; Rongwei Fu; Daniel W Haupt Journal: Psychiatr Res Clin Pract Date: 2020-10-16